• Loading stock data…

ProMIS Neurosciences Announces First Quarter 2022 Results

Last Updated on May 13, 2022 by GlobeNewsWire

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2021.




Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: